secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001193125-26-041190
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 3.02, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing
--------------------------------------------------------------------------------

- Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
- Erigen owns 61.3% of outstanding shares (13.48M total); its members Angel and Lotus Capital to own ~35.9% and 25.5%.
- Geoff Nichol resigned from Board; Michael Raab stepped down as Chair; Stephen Brady appointed Chair.
- Stephen Brady resigned as CEO; Matt Angel appointed President, CEO and Class I director; $650k salary, 50% bonus, 269,621 option.
- Issued 6.78M warrants at $18.48/exercise, expiring Feb 3 2031, to existing shareholders as a dividend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/0001193125-26-041190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/d159400d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-041190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer